| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.052 | 0.3 |
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | -0.043 | 0.3 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.3 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.037 | 0.3 |
| mRNA | Doxorubicin | FIMM | pan-cancer | AAC | -0.16 | 0.3 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.036 | 0.3 |
| mRNA | BI-2536 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.3 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.049 | 0.3 |
| mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | -0.056 | 0.3 |